NovoCure Limited (NASDAQ:NVCR) Stock Has Consensus Price Target of $21.20 According to Analysts

Posted by Geri Gentry on Sep 27th, 2026

Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $21.20.

NVCR has been the subject of a number of research reports. Wall Street Zen downgraded shares of NovoCure from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. Wedbush lifted their price target on shares of NovoCure from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. JPMorgan Chase & Co. began coverage on NovoCure in a research note on Monday, July 13th. They issued a “neutral” rating and a $17.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NovoCure in a report on Thursday, August 27th. Finally, HC Wainwright set a $32.00 target price on NovoCure in a research report on Friday, July 24th.

Get Our Latest Stock Report on NVCR

Institutional Investors Weigh In On NovoCure

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in shares of NovoCure by 346.7% during the 1st quarter. SG Americas Securities LLC now owns 1,245,541 shares of the medical equipment provider’s stock valued at $13,576,000 after buying an additional 966,735 shares in the last quarter. Quantinno Capital Management LP lifted its holdings in NovoCure by 23.7% during the 1st quarter. Quantinno Capital Management LP now owns 2,487,376 shares of the medical equipment provider’s stock worth $27,112,000 after purchasing an additional 477,128 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in NovoCure by 27.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 960,056 shares of the medical equipment provider’s stock worth $10,462,000 after purchasing an additional 207,913 shares during the period. Renaissance Technologies LLC boosted its stake in NovoCure by 11.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,551,554 shares of the medical equipment provider’s stock worth $16,912,000 after purchasing an additional 163,800 shares during the period. Finally, Legal & General Group Plc grew its holdings in NovoCure by 65.6% during the 4th quarter. Legal & General Group Plc now owns 406,664 shares of the medical equipment provider’s stock valued at $5,258,000 after buying an additional 161,095 shares in the last quarter. Hedge funds and other institutional investors own 84.61% of the company’s stock.

NovoCure Stock Down 2.2%

NVCR stock opened at $15.84 on Tuesday. The stock has a market cap of $1.84 billion, a P/E ratio of -12.18 and a beta of 1.01. The company has a current ratio of 2.89, a quick ratio of 2.70 and a debt-to-equity ratio of 0.58. The stock’s fifty day simple moving average is $16.79 and its two-hundred day simple moving average is $15.42. NovoCure has a 1-year low of $9.82 and a 1-year high of $21.45.

NovoCure (NASDAQ:NVCR – Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.20. The firm had revenue of $183.58 million during the quarter, compared to analyst estimates of $172.44 million. NovoCure had a negative return on equity of 44.00% and a negative net margin of 21.25%.The business’s revenue was up 15.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.36) EPS. Analysts expect that NovoCure will post -1.21 EPS for the current year.

About NovoCure

(Get Free Report)

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes Tumor Treating Fields (TTFields), a noninvasive therapy that uses low-intensity, intermediate-frequency electric fields to disrupt the division of cancer cells. The company’s technology is designed to be used alongside other cancer treatments and is delivered through a portable device and transducer arrays placed on the patient’s body.

NovoCure’s principal commercial products include Optune Gio, used with other treatments for adults with certain forms of glioblastoma, and Optune Lua, approved in the United States for use with certain therapies in adults with unresectable, locally advanced or metastatic malignant pleural mesothelioma.